Luis Pareras
Fondateur chez Invivo Capital Partners SGEIC SA
Profil
Luis Pareras is the founder and the Managing Partner at Invivo Capital Partners SGEIC SA, a firm founded in 2019.
He is currently the Director at Pulmobiotics SL, Gyala Therapeutics SL, and Telum Therapeutics SL.
Previously, he worked as a Director at Minoryx Therapeutics SL.
Dr. Pareras holds an MBA from the Instituto de Estudios Superiores de la Empresa, which he received in 2004.
Postes actifs de Luis Pareras
| Sociétés | Poste | Début |
|---|---|---|
Pulmobiotics SL
 Pulmobiotics SL BiotechnologyHealth Technology Pulmobiotics SL operates as a spin off company. The firm uses its technology to discover and develop novel treatments and vaccines for respiratory diseases. The company was founded by Maria Lluch and Lluis Serrano and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
Invivo Capital Partners SGEIC SA
 Invivo Capital Partners SGEIC SA Investment ManagersFinance Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain. | Fondateur | 01/03/2019 |
Telum Therapeutics SL
 Telum Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez. | Directeur/Membre du Conseil | - |
Gyala Therapeutics SL
 Gyala Therapeutics SL BiotechnologyHealth Technology Gyala Therapeutics SL develops CAR-T therapies for treating hematological malignancies. The company is based in Barcelona, Spain. Claudio Santos has been the CEO of the Spanish company since 2020. | Directeur/Membre du Conseil | - |
Anciens postes connus de Luis Pareras
| Sociétés | Poste | Fin |
|---|---|---|
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
Formation de Luis Pareras
| Instituto de Estudios Superiores de la Empresa | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Health Technology |
Invivo Capital Partners SGEIC SA
Invivo Capital Partners SGEIC SA Investment ManagersFinance Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain. | Finance |
Pulmobiotics SL
Pulmobiotics SL BiotechnologyHealth Technology Pulmobiotics SL operates as a spin off company. The firm uses its technology to discover and develop novel treatments and vaccines for respiratory diseases. The company was founded by Maria Lluch and Lluis Serrano and is headquartered in Barcelona, Spain. | Health Technology |
Gyala Therapeutics SL
Gyala Therapeutics SL BiotechnologyHealth Technology Gyala Therapeutics SL develops CAR-T therapies for treating hematological malignancies. The company is based in Barcelona, Spain. Claudio Santos has been the CEO of the Spanish company since 2020. | Health Technology |
Telum Therapeutics SL
Telum Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez. | Commercial Services |
